Marie-Pier St-Laurent, MD, FRCSC, explains how NeoBLAST combines imaging, TURBT, and ctDNA to identify candidates for bladder-sparing surveillance.
|Videos|July 22, 2022
Dr. Ghali on the potential of antibody-drug conjugates in variant histology bladder cancer
Author(s)Urology Times staff
Advertisement
In this video, Fed Ghali, MD, a urologic oncology fellow at the University of Washington, says that variant histology bladder cancers express Nectin-4 and Trop-2, which are cell surface targets of the FDA-approved antibody-drug conjugates, enfortumab-vedotin (Padcev) and sacituzumab govitecan (Trodelvy), respectively. Ghali presented the abstract, “Antibody-drug conjugates and variant histology muscle-invasive bladder cancer: are the targets present in primary and/or metastatic tumors?” at the 2022 AUA Annual Meeting (
Advertisement
Related to this article
Mark D. Tyson, II, MD, MPH, reviews emerging bladder-sparing therapies for NMIBC, highlighting cretostimogene data, treatment sequencing, and the need for comparative trials.
This FAQ outlines key recommendations and practical takeaways from the AUA/SUO guideline amendment on the diagnosis and treatment of NMIBC.
Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.
John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
Armine K. Smith, MD, discusses the importance of integrating sexual health into bladder cancer care, including proactive counseling, preservation strategies, and multidisciplinary support.
One year following the approval of the gemcitabine intravesical system, Joseph Jacob, MD, reflects on the expanding treatment landscape in BCG-unresponsive NMIBC.
The PDUFA target action date is in the fourth quarter of 2026.
Advertisement
Advertisement